Drug Patents owned by Cumberland Pharms

1. List of Acetadote drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399445 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(2 years from now)

US8653061 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(2 years from now)

US8148356 CUMBERLAND PHARMS Acetylcysteine composition and uses therefor
May, 2026

(3 years from now)

US9327028 CUMBERLAND PHARMS Acetylcysteine compositions and methods of use thereof
Jul, 2031

(8 years from now)

US8722738 CUMBERLAND PHARMS Acetycysteine compositions and methods of use thereof
Apr, 2032

(9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions; Composition and method for providing a reduction in side effects for human patients in need of acetylcysteine therapy

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ACETADOTE before it's patent expiration?
More Information on Dosage

2. List of Caldolor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138404 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9114068 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US8735452 CUMBERLAND PHARMS Treating patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9649284 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US8871810 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9295639 CUMBERLAND PHARMS Treating critically ill patients with intravenous ibuprofen
Sep, 2029

(6 years from now)

US9012508 CUMBERLAND PHARMS Administration of intravenous ibuprofen
Sep, 2030

(7 years from now)

US9072661 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(9 years from now)

US9072710 CUMBERLAND PHARMS Injectable ibuprofen formulation
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
M Nov 19, 2024

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation and/or fever with intravenous ibuprofen such that mean arterial blood pressure does not increase the dosage interval; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity; Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics in a critically ill patient with intravenous ibuprofen in need thereof; Methods of treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition; Methods of making aqueous composition and treating pain, inflammation, fever, patent ductus arteriosis with aqueous composition

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

3. List of Vibativ drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6635618 CUMBERLAND PHARMS Glycopeptide phosphonate derivatives
Sep, 2023

(7 months from now)

US7531623 CUMBERLAND PHARMS Hydrochloride salts of a glycopeptide phosphonate derivative
Jan, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6858584 CUMBERLAND PHARMS Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
Aug, 2022

(5 months ago)

Drugs and Companies using TELAVANCIN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 September, 2009

Treatment: Method for treating bacterial infection

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in